PDE5A and melanoma: For nonlocalized melanoma, the result of 3 databases showed a decreased risk with PDE5 inhibitors (OR: 0.62; 95%CI: 0.39–0.98), while no statistically significant heterogeneity found (I2 = 0%, P = .83) (Fig. 2B and C).